{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:33:09Z","timestamp":1786793589006,"version":"build-2736575974"},"reference-count":60,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,5,24]]},"DOI":"10.1080\/14656566.2023.2206014","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T12:32:50Z","timestamp":1682080370000},"page":"959-967","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults"],"prefix":"10.1080","volume":"24","author":[{"given":"Rithi J.","family":"Chandy","sequence":"first","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Bridgeman","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Godinich","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]},{"name":"Wake Forest University School of Medicine","place":["Winston-Salem, USA"]},{"name":"Wake Forest University School of Medicine","place":["Winston Salem, USA"]},{"name":"University of Southern Denmark","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0439-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.5.1473264"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040728"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.590475"},{"key":"e_1_3_4_8_1","unstructured":"Calcipotriene and Betamethasone. Lexi-Drugs. Hudson OH: lexicomp 2023. http:\/\/online.lexi.com. Updated Jan 12 2022. Accessed Jan 9 2023."},{"key":"e_1_3_4_9_1","unstructured":"Tapinarof. Lexi-Drugs. Hudson OH: lexicomp 2023. https:\/\/online.lexi.com.\/ Updated Nov 4 2022. Accessed Jan 9 2023."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221137750"},{"key":"e_1_3_4_11_1","unstructured":"Roflumilast (Topical). Lexi-Drugs Hudson OH: Lexicomp 2023. online.lexi.com\/ Updated Nov 30 2023. Accessed Jan 9 2023."},{"key":"e_1_3_4_12_1","unstructured":"Otezla (APREMILAST) FDA approval history. Drugs.com. https:\/\/www.drugs.com\/history\/otezla.html. Accessed Jan 16 2023."},{"key":"e_1_3_4_13_1","unstructured":"Apremilast. Lexi-drugs. Hudson OH: Lexicomp 2023. http:\/\/on.line.lexi.com\/ Updated Dec 17 2022. Accessed Dec 17 2023."},{"key":"e_1_3_4_14_1","unstructured":"U.S. Food and Drug Administration Approves Sotyktu\u2122 (Deucravacitinib) Oral treatment for adults with moderate-to-severe plaque psoriasis. News. https:\/\/news.bms.com\/news\/details\/2022\/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx. Accessed Feb 5 2023."},{"key":"e_1_3_4_15_1","unstructured":"Deucravacitinib. Lexi-Drugs. Hudson OH: lexicomp 2023. http:\/\/online.lexi.com\/. Updated Jan 5 2023. Accessed Jan 9 2023."},{"key":"e_1_3_4_16_1","unstructured":"Farbstein M Can-fite announces positive top-line results from piclidenoson phase III COMFORTTM study in moderate to severe psoriasis. Business Wire. Jun 29 2022. Accessed Jan 29 2023. https:\/\/www.businesswire.com\/news\/home\/20220629005222\/en\/%C2%A0Can-Fite-Announces-Positive-Top-Line-Results-from-Piclidenoson-Phase-III-COMFORT%E2%84%A2-Study-in-Moderate-to-Severe-Psoriasis."},{"key":"e_1_3_4_17_1","unstructured":"Tofacitinib. Lexi-Drugs. Hudson OH: lexicomp. https:\/\/online.lexi.com\/ Updated Jan 14 2023. Accessed Jan 14 2023."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14947"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15218"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5653"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000073"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.14663"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2004.10.004"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048"},{"issue":"12","key":"e_1_3_4_26_1","first-page":"28","article-title":"New and emerging topical therapies for psoriasis and atopic dermatitis","volume":"12","author":"Psomadakis CE","year":"2019","unstructured":"Psomadakis CE, Han G. New and emerging topical therapies for psoriasis and atopic dermatitis. J Clin Aesthet Dermatol. 2019 Dec;12(12):28\u201334.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16798"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.661"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00794-y"},{"key":"e_1_3_4_34_1","unstructured":"FDA Approves Wynzora\u00ae Cream for Plaque Psoriasis. National Psoriasis Foundation. Accessed Jan 9 2023. https:\/\/www.psoriasis.org\/advance\/fda-approves-wynzora-cream-plaque-psoriasis\/"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15632"},{"key":"e_1_3_4_37_1","unstructured":"US Food and Drug Administration. Full prescribing information: zORYVE (roflumilast) cream for topical use. Published 2022. Accessed Oct 31 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215985s000lbl.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3123\/jemsge.34.107"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2005.10.034"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.44.2280"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-017-0077-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"issue":"8","key":"e_1_3_4_43_1","first-page":"888","article-title":"Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study","volume":"12","author":"Gottlieb AB","year":"2013","unstructured":"Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888\u2013897.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X301866"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/906349"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-020-00326-x"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435"},{"key":"e_1_3_4_52_1","unstructured":"Myers Squibb B. SOTYKTUTM (deucravacitinib) tablets for oral use: uS prescribing information. 2022. https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf. Accessed 12 Sep 2022."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21456"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06643-2"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15922"},{"issue":"9","key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ddg.13749","article-title":"Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: results of a prospective study","volume":"17","author":"Falkvoll S","year":"2019","unstructured":"Falkvoll S, Gerdes S, Mrowietz U. Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: results of a prospective study. J Dtsch Dermatol Ges. 2019 Sep;17(9):906\u2013912.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_4_58_1","volume-title":"The National Psoriasis Foundation.","unstructured":"Treatments in phase 1 trials. The National Psoriasis Foundation.National Psoriasis Foundation. https:\/\/www.psoriasis.org\/treatments-in-phase-1-trials\/. Accessed Jan 19, 2023"},{"key":"e_1_3_4_59_1","volume-title":"The National Psoriasis Foundation.","unstructured":"Treatments in phase 2 trials. The National Psoriasis Foundation.National Psoriasis Foundation. https:\/\/www.psoriasis.org\/treatments-in-phase-2-trials\/. Accessed Jan 19, 2023"},{"issue":"4","key":"e_1_3_4_60_1","first-page":"238","article-title":"Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible","volume":"20","author":"Yentzer BA","year":"2009","unstructured":"Yentzer BA, Feldman SR. Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. J DermatolTreat. 2009;20(4):238\u2013240.","journal-title":"J DermatolTreat"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.074"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1271"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2206014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:27:58Z","timestamp":1770406078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2206014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,5,24]]}},"alternative-id":["10.1080\/14656566.2023.2206014"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2206014","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}